Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its ...
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of and ultimately cure neurological diseases. Founded in 2013 with support from Third Rock Ventures, Voyager is headquartered in Cambridge, Massachusetts, and went public in 2015. The company specializes ...Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of and ultimately cure neurological diseases. Founded in 2013 with support from Third Rock Ventures, Voyager is headquartered in Cambridge, Massachusetts, and went public in 2015. The company specializes in gene therapy, using adeno-associated virus (AAV) vectors to deliver genetic treatments. Its lead clinical asset, VY-AADC, is a gene therapy for Parkinson's disease, currently in Phase 1 clinical trials. The preclinical pipeline includes VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, VY-FXN01 for Friedreich's ataxia, and programs targeting tauopathies like Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as spinal muscular atrophy. Voyager has formed strategic collaborations with major pharmaceutical companies, including Neurocrine Biosciences, Pfizer, and Novartis Pharma, to advance the research, development, and commercialization of its gene therapy products. Financially, the company has a market capitalization of approximately $194 million and has invested heavily in R&D, with R&D expenses to revenue over 3.4 times, reflecting its strong focus on innovation. Despite negative profitability metrics, the company maintains a solid current ratio of 7.5, indicating good short-term liquidity. Key leadership includes CEO Alfred W. Sandrock Jr., a physician-scientist with extensive experience in neurology and drug development. Voyager's vision is to provide transformative treatments for millions affected by neurological disorders, and its state-of-the-art headquarters includes advanced research and process development laboratories. The company continues to advance its pipeline and platform technologies, focusing on capsid engineering and genetic medicine to overcome delivery challenges in the brain.
